Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.
Novartis has struck another deal to build its position in radiopharmaceuticals, agreeing to pay $1 billion upfront for radioligand therapy (RLT) developer Mariana Oncology
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.